Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05043883
Other study ID # CPVI-002
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 15, 2021
Est. completion date June 22, 2022

Study information

Verified date March 2022
Source CathVision ApS
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A prospective, multi-center study with the CathVision Cube® system and the PVI Analyzer software in radiofrequency (RF), cryo-balloon (CB), and Pulse Field Ablation (PFA) procedures.


Description:

Subjects with paroxysmal or persistent atrial fibrillation (AF) who are indicated to undergo first pulmonary vein isolation (PVI) procedure and meet all eligibility criteria will be enrolled in the Study. Intracardiac signals will be passively recorded using the investigational CathVision Cube® System in parallel with the conventional (CE marked) EP recording system. The investigational device will not be used for direct clinical care decisions or therapy. The validation of the automated algorithm for PVI will be performed offline The primary objective is to validate the PVI Analyzer software with a novel EP recording system (CathVision Cube® System) for assisting assessment of isolation status following PVI ablation. The secondary objective is to determine the feasibility of "real-time" assessment of PVI analysis and rhythm dependent performance using the PVI Analyzer and CathVision Cube® System.


Recruitment information / eligibility

Status Completed
Enrollment 101
Est. completion date June 22, 2022
Est. primary completion date June 22, 2022
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Eligible subjects will meet all of the following inclusion criteria: 1. Subjects undergoing first-time pulmonary vein isolation indicated by investigator for the treatment of atrial fibrillation 2. Male or non-pregnant female aged =21 years. 3. Able and willing to provide written informed consent prior to any clinical investigation related procedure Eligible subjects will not meet any of the following exclusion criteria: 1. Pregnant or nursing subjects. 2. Current participation in another investigational drug or device study that interferes with this Study. 3. Subjects who, in the opinion of the investigator, are not candidates for this Study. 4. Patients who have had a prior ablation procedure 5. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results. 6. Life expectancy less than 12 month 7. Subjects who, in the opinion of the investigator, are considered part of any vulnerable population.

Study Design


Intervention

Device:
CathVision Cube® system
Intracardiac signals will be passively recorded using the investigational CathVision Cube® System in parallel with the commercial (bearing CE mark) EP recording systems LabSystem Pro, Boston Scientific EP, or EP-Tracer, Schwarzer Cardiotek. The investigational device will not be used for direct clinical care decisions or therapy. The validation of the PVI Analyzer will be performed offline and retrospectively.

Locations

Country Name City State
Belgium AZ Sint-Jan Hospital Brugge
Belgium Universitair Ziekenhuis Brussel Brussels
Belgium Ghent University Hospital Ghent
France Clinique Pasteur Toulouse, Toulouse

Sponsors (2)

Lead Sponsor Collaborator
CathVision ApS AKRN Scientific Consulting, S.L.

Countries where clinical trial is conducted

Belgium,  France, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary performance objective is to validate the PVI Analyzer software with a novel EP recording system (CathVision Cube® System) for assessment of isolation status following PVI ablation. Sensitivity and specificity of PVI Analyzer classification of isolation status following PVI ablation using data from the investigational CathVision Cube System. Specificity is defined as the ratio of correct negative (non-isolated) predictions among data points from non-isolated veins. Sensitivity is defined as the ratio of correct positive (isolated) data points from isolated veins. Classification is performed using recorded data before and after the isolation of each available pulmonary vein independently. From EP procedure until study completion at discharge; an average of 24 hours.
Primary The safety endpoint of the Study will evaluate the adverse events and/or device malfunctions reported with the use of the CathVision Cube® System. Evaluation of adverse events and/or device malfunctions reported with the use of the CathVision Cube® System during the procedure until discharge. From EP procedure until study completion at discharge; an average of 24 hours.
Secondary Accuracy of automated PVI Analyzer classification of PV isolation in SR during Cryo-balloon ablation Sensitivity and specificity of PVI Analyzer classification of isolation status within the Cryo-balloon ablation subgroup. Classification, sensitivity and specificity are defined in the same way as for the primary endpoint. From EP procedure until study completion at discharge; an average of 24 hours.
Secondary Accuracy of automated PVI Analyzer classification of PV isolation in SR during RF ablation Sensitivity and specificity of PVI Analyzer classification of isolation status within the RF ablation subgroup. Classification, sensitivity and specificity are defined in the same way as for the primary endpoint. From EP procedure until study completion at discharge; an average of 24 hours.
Secondary Assessment of automated PVI Analyzer classification of PV isolation in SR after PFA Sensitivity and specificity of PVI Analyzer classification of isolation status within the PFA ablation subgroup. Classification, sensitivity and specificity are defined in the same way as for the primary endpoint. From EP procedure until study completion at discharge; an average of 24 hours.
Secondary Feasibility of "real-time" assessment of isolation Retest accuracy of PVI Analyzer classification of isolation status at different timepoints before, during and after ablation.
The accuracy is defined as the agreement of re-classification of pairs of non-overlapping samples before, during and after ablation.
From EP procedure until study completion at discharge; an average of 24 hours.
Secondary Automated PVI Analyzer classification of PV isolation in NSR Sensitivity and specificity of PVI Analyzer classification of isolation status within the subgroup of data recorded in non-sinus rhythm.
Non-sinus rhythm is defined as any rhythm not regarded as sinus rhythm, including atrial fibrillation, typical- and atypical atrial flutter. Classification, sensitivity and specificity are measured in the same way as for primary endpoint.
From EP procedure until study completion at discharge; an average of 24 hours.
Secondary PVI Analyzer classification accuracy at the time of expert-defined isolation Sensitivity of PVI Analyzer analysis to identify expert-defined isolation during PVI ablation. From EP procedure until study completion at discharge; an average of 24 hours.
Secondary Comparison of device performance with conventional system Specificity and sensitivity of PVI Analyzer analysis to identify isolation using data from the conventional system. From EP procedure until study completion at discharge; an average of 24 hours.
See also
  Status Clinical Trial Phase
Completed NCT05970120 - A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter N/A
Recruiting NCT06014996 - Comparison of PFA vs. RFA in Patients With Symptomatic Paroxysmal Atrial Fibrillation. N/A
Completed NCT03624881 - Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU) Phase 4
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Recruiting NCT05905835 - Treatment of PAF With the Synaptic System N/A
Active, not recruiting NCT05534581 - SINGLE SHOT CHAMPION Phase 4
Active, not recruiting NCT05618340 - PFA for Paroxysmal Atrial Fibrillation N/A
Not yet recruiting NCT05024630 - Renal Denervation and pUlmonary Vein isolAtion With cryoabLation on Patients With Atrial Fibrillation and hypErtension N/A
Completed NCT02610803 - Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke N/A
Completed NCT01913522 - Cryoballoon vs. Irrigated Radiofrequency Catheter Ablation: Double Short vs. Standard Exposure Duration N/A
Withdrawn NCT01917981 - Testing the Accuracy of a Personal Heart Rhythm Monitor to Detect Prolonged Paroxysmal Atrial Fibrillation Phase 3
Terminated NCT01925885 - Focal Impulse and Rotor Modulation Ablation Trial for Treatment of Paroxysmal Atrial Fibrillation (FIRMAT-PAF) N/A
Completed NCT01842529 - Botulinum Toxin Injection in Epicardial Fat Pads To Treat Atrial Fibrillation After Cardiac Surgery Phase 2
Completed NCT01693107 - Atrial Fibrillation Force Contact Ablation Study
Completed NCT00971204 - Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation Phase 2
Recruiting NCT05172765 - Biomarker-Guided Optimization of Transcutaneous Vagal Stimulation for Atrial (BiG tVNS-AF) N/A
Recruiting NCT04529785 - Added Value of Vein of Marshal Ethanol Infusion Compared to Superior Vena Cava Isolation Alone in Patients Undergoing Repeat Ablation for Recurrent Paroxysmal Atrial Fibrillation Despite Durable PV Isolation N/A
Completed NCT04022954 - HD Mapping of Atrial Fibrillation in Asia Pacific
Completed NCT00964392 - NAVISTAR® THERMOCOOL® Catheter Post Approval Registry Phase 4
Recruiting NCT03912324 - Computed Tomogram Myocardial Thickness Map Guided pulmOnary Vein iSolaTion vs. Empirical Pulmonary Vein Isolation in Cryoballoon Ablation for Paroxysmal Atrial Fibrillation (UTMOST AF II) N/A